Home > Dermatology > AAD 2020 > AAD 2020 Highlights Podcast

AAD 2020 Highlights Podcast

Presented By
Dr Rachel Giles, Medicom
Conference
AAD 2020
  In this episode, Dr Rachel Giles guides you through the following sessions: Simpson EL, et al. Baricitinib, an Oral, Reversible Janus Kinase-1 and -2 Inhibitor, for Atopic Dermatitis: Head and Neck Response Across Two Phase 3 Studies. P15059; AAD Virtual Meeting Experience, 12-14 June 2020. Khanna R, et al. Intranasal butorphanol as a rescue therapy for the treatment of intractable pruritus. P17132, AAD Virtual Meeting Experience, 12-14 June 2020. Lewinson RT, et al. Depression as a risk factor for the development of psoriasis. P16742, AAD Virtual Meeting Experience, 12-14 June 2020. Warren RB. Risankizumab versus secukinumab in patients with moderate-to-severe plaque psoriasis: a phase 3 trial. Late-breaking abstract, AAD Virtual Meeting Experience, 12-14 June 2020. Hu J, et al. Impact of Obesity and Body Parameters on Pembrolizumab Toxicity and Efficacy in Patients wi...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on